DGF Stoess AG - GELITA Health Initiative

Collagen hydrolysate research, osteoarthritis treatment

GELITA Health Initiative (GHI) was established by DGF STOESS AG (GELITA Group), a manufacturer of gelatine. The initiative supports research in collagen hydrolysate and its use for degenerative diseases. DGF STOESS AG, headquartered in Eberbach, Germany, is the holding of the worldwide GELITA group.

Michael Teppner, General Manager
Werner Badziong, Dr., Medical Affairs
Flechsenhar, Dr., Medical Affairs

Uferstraße 7
69412 Eberbach
Germany
Phone: +49-6271-841-602
Fax: +49-6271-844-602

Experiments strongly suggest a protective and cartilage-restorative role for collagen hydrolysate and clinical studies have suggested a pain-relieving effect on the locomotor system. Due to the specific properties of collagen hydrolysate, there is an opportunity to intervene in the degenerative process of osteoarthritis. Therefore, collagen hydrolysate may be an effective nutritional supplement for those suffering from osteoarthritis.

The gelatine division of DGF Stoess AG, Gelita Group, is the leading manufacturer of gelatine worldwide. It is involved in the research, production and distribution of some 250 types of gelatine, including collagen hydrolysate.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.